

Barry Reisberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6752237/publications.pdf>

Version: 2024-02-01

87
papers

9,611
citations

101543

36
h-index

85541

71
g-index

99
all docs

99
docs citations

99
times ranked

9023
citing authors

#	ARTICLE	IF	CITATIONS
1	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.8	1,863
2	Memantine in Moderate-to-Severe Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2003, 348, 1333-1341.	27.0	1,814
3	Functional Assessment Staging (FAST) in Alzheimer's Disease: Reliability, Validity, and Ordinality. <i>International Psychogeriatrics</i> , 1992, 4, 55-69.	1.0	447
4	Outcome over seven years of healthy adults with and without subjective cognitive impairment. <i>Alzheimer's and Dementia</i> , 2010, 6, 11-24.	0.8	447
5	FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 811-822.	6.4	409
6	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311.	0.8	375
7	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S63-S86.	2.6	317
8	Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. <i>International Psychogeriatrics</i> , 2008, 20, 1-16.	1.0	259
9	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.8	232
10	The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2008, 4, S98-S108.	0.8	224
11	Neuropsychological Prediction of Decline to Dementia in Nondemented Elderly. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1999, 12, 168-179.	2.3	202
12	Functional and Global Evaluations: Discussion. <i>International Psychogeriatrics</i> , 1997, 9, 177-178.	1.0	187
13	Positron Emission Tomography in the Study of Aging and Senile Dementia. <i>Neurobiology of Aging</i> , 1980, 1, 127-131.	3.1	176
14	The GDS/FAST Staging System. <i>International Psychogeriatrics</i> , 1997, 9, 167-171.	1.0	166
15	A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease. <i>Archives of Neurology</i> , 2006, 63, 49.	4.5	164
16	Evidence and mechanisms of retrogenesis in Alzheimer's and other dementias: Management and treatment import. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2002, 17, 202-212.	1.9	148
17	Subjective Memory Complaints: Presence, Severity and Future Outcome in Normal Older Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 177-184.	1.5	148
18	Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. <i>Drug Development Research</i> , 1988, 15, 101-114.	2.9	140

#	ARTICLE	IF	CITATIONS
19	Functional Staging of Dementia of the Alzheimer Type. <i>Annals of the New York Academy of Sciences</i> , 1984, 435, 481-483.	3.8	139
20	The Alzheimer's Disease Activities of Daily Living International Scale (ADL-IS). <i>International Psychogeriatrics</i> , 2001, 13, 163-181.	1.0	128
21	Global measures: utility in defining and measuring treatment response in dementia. <i>International Psychogeriatrics</i> , 2007, 19, 421-456.	1.0	93
22	Mild cognitive impairment (MCI): a historical perspective. <i>International Psychogeriatrics</i> , 2008, 20, 18-31.	1.0	93
23	A Two-Year Longitudinal Study of Cognitive Function in Normal Aging and Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1993, 6, 84-96.	2.3	81
24	The Neglected Half of Alzheimer Disease: Cognitive and Functional Concomitants of Severe Dementia. <i>Journal of the American Geriatrics Society</i> , 1994, 42, 1266-1272.	2.6	79
25	Mortality and Temporal Course of Probable Alzheimer's Disease: A 5-Year Prospective Study. <i>International Psychogeriatrics</i> , 1996, 8, 291-311.	1.0	75
26	Robust and conventional neuropsychological norms: Diagnosis and prediction of age-related cognitive decline.. <i>Neuropsychology</i> , 2008, 22, 469-484.	1.3	74
27	The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale. <i>International Psychogeriatrics</i> , 1996, 8, 247-266.	1.0	71
28	Contractures and Loss of Function in Patients with Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 1995, 43, 650-655.	2.6	66
29	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
30	Longitudinal course of normal aging and progressive dementia of the Alzheimer's type: A prospective study of 106 subjects over a 3.6 year mean interval. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1986, 10, 571-578.	4.8	61
31	Nimodipine in the Treatment of Probable Alzheimer's Disease. <i>Clinical Drug Investigation</i> , 1996, 11, 185-195.	2.2	53
32	Towards a Science of Alzheimer's Disease Management: A Model Based Upon Current Knowledge of Retrogenesis. <i>International Psychogeriatrics</i> , 1999, 11, 7-23.	1.0	49
33	Diagnostic Criteria in Dementia: A Comparison of Current Criteria, Research Challenges, and Implications for DSM-V. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2006, 19, 137-146.	2.3	45
34	Institutionalization of Alzheimer's Disease Patients. <i>Home Health Care Services Quarterly</i> , 1987, 8, 23-51.	0.7	44
35	Clinical Evaluation of Global Change in Alzheimer's Disease: Identifying Consensus. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1996, 9, 176-180.	2.3	44
36	Ecopsychosocial Interventions in Cognitive Decline and Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 502-507.	1.9	43

#	ARTICLE	IF	CITATIONS
37	Reliability of Routine Clinical Instruments for the Assessment of Alzheimer's Disease Administered by Telephone. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998, 11, 18-24.	2.3	41
38	Neuromotor Changes in Alzheimer's Disease: Implications for Patient Care. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1997, 10, 93-98.	2.3	35
39	Neuropathological Assessments: Discussion. <i>International Psychogeriatrics</i> , 1997, 9, 269-272.	1.0	35
40	The BEHAVE-AD Assessment System: A Perspective, A Commentary on New Findings, and A Historical Review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 89-146.	1.5	34
41	Temporal Order of Cognitive and Functional Loss in a Nursing Home Population. <i>Journal of the American Geriatrics Society</i> , 1995, 43, 974-978.	2.6	33
42	Cognitive decline in advanced age: Future directions for the psychometric differentiation of normal and pathological age changes in cognitive function. <i>Developmental Neuropsychology</i> , 1986, 2, 309-322.	1.4	30
43	Age-associated memory impairment: The clinical syndrome. <i>Developmental Neuropsychology</i> , 1986, 2, 401-412.	1.4	30
44	Equivalent spatial-rotation deficits in normal aging and alzheimer's disease. <i>Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology</i> , 1988, 10, 387-399.	1.1	29
45	Overview of Methodologic Issues for Pharmacologic Trials in Mild, Moderate, and Severe Alzheimer's Disease. <i>International Psychogeriatrics</i> , 1996, 8, 159-193.	1.0	28
46	Pharmacologic Treatment of Alzheimer's Disease: A Methodologic Critique Based Upon Current Knowledge of Symptomatology and Relevance for Drug Trials. <i>International Psychogeriatrics</i> , 1992, 4, 9-42.	1.0	25
47	Behavioral Disturbances of Dementia: An Overview of Phenomenology and Methodologic Concerns. <i>International Psychogeriatrics</i> , 1996, 8, 169-182.	1.0	25
48	Neuroimaging and Electrophysiology: Discussion. <i>International Psychogeriatrics</i> , 1997, 9, 247-252.	1.0	20
49	Utility of Developmental Reflexes in the Differential Diagnosis and Prognosis of Incontinence in Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1997, 10, 22-28.	2.3	19
50	Neurologic Markers of the Progression of Alzheimer's Disease. <i>International Psychogeriatrics</i> , 1997, 9, 297-306.	1.0	16
51	Subjective memory complaints predict baseline but not future cognitive function over three years: results from the Western Australia Memory Study. <i>International Psychogeriatrics</i> , 2019, 31, 513-525.	1.0	13
52	Reliability of the Modified Ordinal Scales of Psychological Development: A Cognitive Assessment Battery for Severe Dementia. <i>International Psychogeriatrics</i> , 1996, 8, 225-231.	1.0	12
53	Translations of Measurements and Scales: Opportunities and Diversities. <i>International Psychogeriatrics</i> , 2000, 12, 391-394.	1.0	11
54	Commentary on "A roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy import. , 2009, 5, 154-156.		9

#	ARTICLE	IF	CITATIONS
55	Do Many of the Behavioral and Psychological Symptoms of Dementia Constitute a Distinct Clinical Syndrome? Current Evidence Using the BEHAVE-AD. <i>International Psychogeriatrics</i> , 2000, 12, 155-164.	1.0	8
56	Dementia service centres in Austria: A comprehensive support and early detection model for persons with dementia and their caregivers – theoretical foundations and model description. <i>Dementia</i> , 2015, 14, 513-527.	2.0	8
57	Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 43, 100-117.	1.5	8
58	Clinicopathological Staging of Dynamics of Neurodegeneration and Neuronal Loss in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 21-44.	1.7	8
59	Immune dysfunctions: New targets of drug discovery for Alzheimer's disease and other cognitive disorders. <i>Drug Development Research</i> , 1988, 15, 95-99.	2.9	7
60	Correlation between functional assessment staging and the 'Basic Age' by the Binet scale supports the retrogenesis model of Alzheimer's disease: a preliminary study. <i>Psychogeriatrics</i> , 2003, 3, 82-87.	1.2	6
61	Neuropsychological and Neuropsychiatric Prediction of Global Cognitive Status Among Older Spanish-Speaking Hispanics and English-Speaking Whites. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 266-275.	2.3	6
62	Psychometric Cognitive Decline Precedes the Advent of Subjective Cognitive Decline in the Evolution of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 16-21.	1.5	6
63	Behavioral Symptoms in Dementia: Community-Based Research. <i>International Psychogeriatrics</i> , 1997, 8, 363-366.	1.0	5
64	New and Promising Modalities for Assessment of Behavioral and Psychological Symptoms of Dementia. <i>International Psychogeriatrics</i> , 2000, 12, 175-178.	1.0	5
65	Guidelines for Drug Trials in the Treatment of Age-Associated Cognitive Decline and Alzheimer's Disease. <i>Drug Information Journal</i> , 1985, 19, 405-420.	0.5	4
66	Behavioral Intervention Approaches to the Treatment and Management of Alzheimer's Disease: A Research Agenda. <i>International Psychogeriatrics</i> , 1996, 8, 39-44.	1.0	4
67	Fibrillar amyloid- β^2 affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration. <i>Acta Neuropathologica</i> , 2001, 101, 585-590.	7.7	4
68	Clinical Diagnosis of Dementia: A Review. , 2002, , 69-141.		4
69	Clinical Assessment of Cognitive Decline in Normal Aging and Primary Degenerative Dementia: Concordant Ordinal Measures. , 1985, , 333-338.		3
70	Legal issues in Alzheimer's disease. <i>American Journal of Alzheimer S Care and Related Disorders & Research</i> , 1988, 3, 24-36.	0.1	2
71	The 1991 IPA Research Awards in Psychogeriatrics. <i>International Psychogeriatrics</i> , 1992, 4, 141-146.	1.0	2
72	Introduction: The 1995 Research Awards in Psychogeriatrics. <i>International Psychogeriatrics</i> , 1996, 8, 9-12.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Clinical Diagnosis of Dementia: A Review. , 2003, , 69-141.		2
74	Staging: Relevance for Trial Design in Vascular Burden of the Brain. International Psychogeriatrics, 2003, 15, 231-239.	1.0	1
75	P4153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Non-AD in Memory Clinic and Community-Based Cohorts. Alzheimer's and Dementia, 2016, 12, P1073.	0.8	1
76	The 1993 Research Awards in Psychogeriatrics. International Psychogeriatrics, 1994, 6, 7-11.	1.0	0
77	Introduction: The 1997 IPA/Bayer Research Awards. International Psychogeriatrics, 1997, 9, 251-254.	1.0	0
78	Prognosis of Dementia. , 0, , 308-312.		0
79	Appendix"International Psychogeriatric Association (IPA). , 0, , 799-800.		0
80	The 2003 IPA Research Awards in Psychogeriatrics. International Psychogeriatrics, 2004, 16, 9-12.	1.0	0
81	Commentary on "Diagnosis of Alzheimer's disease: Two decades of progress."Symptomatology and biomolecular basis of Alzheimer's: A synthesis. , 2005, 1, 102-106.		0
82	2. Alzheimer disease: the clinical syndrome; diagnostic and etiologic importance. Acta Neurologica Scandinavica, 2009, 82, 2-4.	2.1	0
83	P2-303: Effects of a comprehensive, individualized person-centered management program on persons with moderately severe Alzheimer's disease: A randomized controlled trial-comprehensive study findings. , 2015, 11, P608-P609.		0
84	F10402: Global Deterioration Scale (GDS) Stage 2: Persons with Subjective Cognitive Impairment (SCI) Only Show Significant Declines in GDS Staging System Measures Over a 2-Year Interval. Alzheimer's and Dementia, 2016, 12, P167.	0.8	0
85	[F10104]: COMPREHENSIVE, INDIVIDUALIZED, PERSON-CENTERED MANAGEMENT PROGRAM IN SUBJECTS TREATED WITH MEMANTINE ENHANCES FUNCTIONING BY 75%, IN COMPARISON WITH MEMANTINE TREATMENT ALONE, IN PERSONS WITH MODERATE-TO-SEVERE AD IN 28-WEEK RANDOMIZED CONTROLLED TRIALS. Alzheimer's and Dementia. 2017. 13. P173.	0.8	0
86	F30304: COMPREHENSIVE, INDIVIDUALIZED, PERSON-CENTERED MANAGEMENT PROGRAM REDUCES RISK OF HOSPITALIZATION BY 67% AND EMERGENCY ROOM VISITS BY 50% IN COMMUNITY-RESIDING, ADVANCED AD PERSONS IN A 28-WEEK RANDOMIZED, CONTROLLED TRIAL. Alzheimer's and Dementia, 2018, 14, P1001.	0.8	0
87	Emergency Issues in the Assessment and Management of Alzheimer's Disease. Emergency Health Services Review, 1986, 3, 55-76.	0.0	0